<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Vecuronium: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Vecuronium: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Vecuronium: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="10041" href="/d/html/10041.html" rel="external">see "Vecuronium: Drug information"</a> and <a class="drug drug_patient" data-topicid="10987" href="/d/html/10987.html" rel="external">see "Vecuronium: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F5708859"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Experienced personnel:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">This drug should be administered by adequately trained individuals familiar with its actions, characteristics, and hazards.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1062905"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Neuromuscular Blocker Agent, Nondepolarizing</span>;</li>
<li>
<span class="list-set-name">Skeletal Muscle Relaxant, Paralytic</span></li></ul></div>
<div class="block don drugH1Div" id="F53462619"><span class="drugH1">Dosing: Neonatal</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e257107d-cfc8-4139-8489-2af70c1690f9">Neuromuscular blockade</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Neuromuscular blockade:</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">Intermittent IV: 0.1 mg/kg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20176672']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20176672'])">Ref</a></span>); maintenance: 0.03 to 0.15 mg/kg/dose every 1 to 2 hours as needed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2827933','lexi-content-ref-Eichenwald.2017']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2827933','lexi-content-ref-Eichenwald.2017'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Continuous IV infusion: Initial: 1 to 1.7 <b>mcg</b>/kg/minute (0.06 to 0.1 mg/kg/<b>hour</b>) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1673644','lexi-content-ref-15505447']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1673644','lexi-content-ref-15505447'])">Ref</a></span>); titrate until desired neuromuscular blockade is achieved; some investigators have suggested adjusting rates in 25% to 100% increments (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15505447']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15505447'])">Ref</a></span>); doses ranging from 0.5 to 3 <b>mcg</b>/kg/minute (0.03 to 0.18 mg/kg/<b>hour</b>) have been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1673644','lexi-content-ref-15505447']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1673644','lexi-content-ref-15505447'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dop drugH1Div" id="F233689"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Dose to effect; doses will vary due to interpatient variability. Dosing in obese patients should be calculated using ideal body weight (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17683408']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17683408'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e257107d-cfc8-4139-8489-2af70c1690f9">Neuromuscular blockade</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Neuromuscular blockade: </b></p>
<p style="text-indent:-2em;margin-left:4em;">Infants:</p>
<p style="text-indent:-2em;margin-left:6em;">IV: 0.08 to 0.1 mg/kg/dose, repeat as needed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10446832','lexi-content-ref-17683408']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10446832','lexi-content-ref-17683408'])">Ref</a></span>); <b>Note:</b> If intubation is performed using succinylcholine, the initial dose of vecuronium may be reduced to 0.04 to 0.06 mg/kg with inhalation anesthesia and 0.05 to 0.06 mg/kg with balanced anesthesia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Continuous IV infusion: 0.8 to 1.7 <b>mcg</b>/kg/minute (0.05 to 0.1 mg/kg/<b>hour</b>) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10446832','lexi-content-ref-17683408']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10446832','lexi-content-ref-17683408'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Children and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">IV: 0.08 to 0.1 mg/kg/dose, repeat as needed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10446832','lexi-content-ref-17683408']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10446832','lexi-content-ref-17683408'])">Ref</a></span>); <b>Note:</b> If intubation is performed using succinylcholine, the initial dose of vecuronium may be reduced to 0.04 to 0.06 mg/kg with inhalation anesthesia and 0.05 to 0.06 mg/kg with balanced anesthesia. Children 1 to 10 years may require slightly higher initial doses and more frequent supplementation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Continuous IV infusion: 0.8 to 2.5 <b>mcg</b>/kg/minute (0.05 to 0.15 mg/kg/<b>hour</b>) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10446832','lexi-content-ref-17683408']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10446832','lexi-content-ref-17683408'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51193251"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer's labeling. Although patients with kidney impairment do not experience clinically significant prolongation of neuromuscular blockade with vecuronium, patients who are anephric may have a prolonged clinical duration; as a result, a lower initial dose should be considered.</p></div>
<div class="block dohp drugH1Div" id="F51193252"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer's labeling; however, dose reductions may be necessary in patients with liver disease.</p></div>
<div class="block doa drugH1Div" id="F233674"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="10041" href="/d/html/10041.html" rel="external">see "Vecuronium: Drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Dose to effect; doses will vary due to interpatient variability. Ensure adequate pain control and sedation prior to and during administration neuromuscular blockade to achieve deep sedation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27755068']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27755068'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="75d1b129-8032-4e57-a035-27b22d97af93">Neuromuscular blockade for endotracheal intubation, surgery, or mechanical ventilation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Neuromuscular blockade for endotracheal intubation, surgery, or mechanical ventilation (as adjunct to general anesthesia):</b> IV:</p>
<p style="text-indent:-2em;margin-left:4em;">Tracheal intubation: <b>IV:</b> Initial: 0.08 to 0.1 mg/kg. <b>Note:</b> If intubation is performed using succinylcholine, the initial dose of vecuronium may be reduced to 0.04 to 0.06 mg/kg with inhalation anesthesia and 0.05 to 0.06 mg/kg with balanced anesthesia.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Pretreatment/priming:</i> 10% of intubating dose given 3 to 5 minutes before intubating dose</p>
<p style="text-indent:-2em;margin-left:4em;">Maintenance for continued surgical relaxation (only after return of neuromuscular function): Intermittent dosing: 0.01 to 0.015 mg/kg <b>or </b>continuous infusion of 0.8 to 1.2 <b>mcg</b>/kg/<b>minute</b> (0.048 to 0.072 <b>mg</b>/kg/<b>hour</b>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> Use lower end of the dosing range when anesthesia is maintained with an inhaled anesthetic agent, with the redosing interval guided by monitoring with a peripheral nerve stimulator.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="61c22ae8-3f3b-4c8d-842a-da6ccbe40121">Intensive care unit paralysis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Intensive care unit paralysis (eg, use for up to 48 hours in patients with early ARDS with PaO<sub>2</sub>/FiO<sub>2</sub> &lt;150, to facilitate mechanical ventilation,</b>
<b>shivering from therapeutic hypothermia) (off-label dosing):</b>
<b>IV:</b> Initial bolus dose: 0.08 to 0.1 mg/kg, then a continuous IV infusion of 0.8 to 1.7 <b>mcg</b>/kg/<b>minute</b> (0.048 to 0.102 <b>mg</b>/kg/<b>hour</b>); monitor depth of blockade every 1 to 2 hours initially until stable dose, then every 8 to 12 hours. Usual maintenance infusion dose range: 0.8 to 1.2 <b>mcg</b>/kg/<b>minute</b> (0.048 to 0.072 <b>mg</b>/kg/<b>hour</b>) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11902255','lexi-content-ref-2574099','lexi-content-ref-23591211','lexi-content-ref-9142020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11902255','lexi-content-ref-2574099','lexi-content-ref-23591211','lexi-content-ref-9142020'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Dosage adjustment</i>: Adjust rate of administration in increments of 0.3 <b>mcg</b>/kg/<b>minute</b> (or 0.018 <b>mg</b>/kg/<b>hour</b>) or by 50% reductions of previous dose according to desired clinical response and possibly using peripheral nerve stimulation response. Discontinue infusion if neuromuscular function does not return (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8835051','lexi-content-ref-9142020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8835051','lexi-content-ref-9142020'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> When possible, minimize depth and duration of paralysis. Stopping the infusion daily for some time until forced to restart based on patient condition is recommended to reduce post-paralytic complications (eg, acute quadriplegic myopathy syndrome [AQMS]) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11902255','lexi-content-ref-27755068','lexi-content-ref-1353252']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11902255','lexi-content-ref-27755068','lexi-content-ref-1353252'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Intermittent bolus dosing</i>: 0.1 to 0.2 mg/kg/dose; may be repeated when neuromuscular function returns (Hunter 1985); for shivering from therapeutic hypothermia may use 8 to 12 mg, repeated as needed to maintain adequate control (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11856794','lexi-content-ref-12847056','lexi-content-ref-19237924']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11856794','lexi-content-ref-12847056','lexi-content-ref-19237924'])">Ref</a></span>)</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990944"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling. However, patients with renal impairment do not experience clinically significant prolongation of neuromuscular blockade with vecuronium; however, in patients who are anephric, the clinical duration is prolonged.</p></div>
<div class="block doha drugH1Div" id="F50988273"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling. However, dosage reduction may be necessary in patients with liver disease.</p></div>
<div class="block adr drugH1Div" id="F233641"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%, postmarketing, and/or case reports: Bradycardia, circulatory shock, edema, flushing, hypersensitivity reaction (including erythema, hypotension, tachycardia, urticaria), pruritus, skin rash</p></div>
<div class="block coi drugH1Div" id="F233655"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;margin-left:0em;display:inline">Hypersensitivity to vecuronium or any component of the formulation</p></div>
<div class="block war drugH1Div" id="F233639"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Anaphylaxis: Severe anaphylactic reactions have been reported with vecuronium use; some life-threatening and fatal. Appropriate emergency treatment (including epinephrine 1 mg/mL) should be immediately available during use. Use caution in patients with previous anaphylactic reactions to other neuromuscular-blocking agents.</p>
<p style="text-indent:-2em;margin-left:4em;">• Prolonged paralysis: Some patients may experience delayed recovery of neuromuscular function after administration (especially after prolonged use). Other factors associated with delayed recovery should be considered (eg, corticosteroid use, disease-related conditions).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Burn injury: Resistance may occur in burn patients (≥20% of total body surface area), usually several days after the injury, and may persist for several months after wound healing (Han 2009).</p>
<p style="text-indent:-2em;margin-left:4em;">• Conditions that may <i>antagonize</i> neuromuscular blockade (decreased paralysis): Respiratory alkalosis, hypercalcemia, demyelinating lesions, peripheral neuropathies, denervation, and muscle trauma may result in antagonism of neuromuscular blockade (ACCM/SCCM/ASHP [Murray 2002]; Greenberg 2013; Miller 2010; Naguib 2002).</p>
<p style="text-indent:-2em;margin-left:4em;">• Conditions that may <i>potentiate</i> neuromuscular blockade (increased paralysis): Electrolyte abnormalities (eg, severe hypocalcemia, severe hypokalemia, hypermagnesemia), neuromuscular diseases, metabolic acidosis, respiratory acidosis, Eaton-Lambert syndrome, and myasthenia gravis may result in potentiation of neuromuscular blockade (Greenberg 2013; Miller 2010; Naguib 2002).</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with hepatic impairment; clinical duration may be prolonged.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: In general, patients with renal impairment do not experience clinically significant prolongation of neuromuscular blockade with vecuronium; however, in patients who are anephric, the clinical duration may be prolonged.</p>
<p style="text-indent:-2em;margin-left:4em;">• Respiratory disease: Use with caution in patients with underlying respiratory disease.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: Use with caution in the elderly, effects and duration are more variable; dosage reduction may be considered.</p>
<p style="text-indent:-2em;margin-left:4em;">• Immobilized patients: Resistance may occur in patients who are immobilized.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pediatric: Children 1-10 years of age may require slightly higher initial doses and slightly more frequent supplementation.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Benzyl alcohol and derivatives: Diluent (bacteriostatic water for injection) contains benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity (“gasping syndrome”) in neonates; the “gasping syndrome” consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP ["Inactive" 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol with caution in neonates. See manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Maintenance of an adequate airway and respiratory support is critical. All patients should receive eye care including liberal use of lubricating drops, gel, or ointment and eyelids should remain closed during continuous neuromuscular blockade to protect against damage to the cornea (ulceration and drying).</p>
<p style="text-indent:-2em;margin-left:4em;">• Experienced personnel: <b>[US Boxed Warning]: Should be administered by adequately trained individuals familiar with its use.</b></p>
<p style="text-indent:-2em;margin-left:4em;">• Risk of medication errors: Accidental administration may be fatal. Confirm proper selection of intended product, store vial so the cap and ferrule are intact and the possibility of selecting the wrong product is minimized, and ensure that the intended dose is clearly labeled and communicated, when applicable.</p></div>
<div class="block foc drugH1Div" id="F233649"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous, as bromide: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 10 mg (1 ea); 20 mg (1 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous, as bromide [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 10 mg (1 ea); 20 mg (1 ea)</p></div>
<div class="block geq drugH1Div" id="F233635"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F16324085"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Vecuronium Bromide Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $4.75 - $10.20</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg (per each): $9.72 - $20.40</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52868585"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous, as bromide: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 10 mg ([DSC])</p></div>
<div class="block admp drugH1Div" id="F52614003"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Parenteral:</p>
<p style="text-indent:-2em;margin-left:4em;">IV bolus: Administer undiluted (reconstituted solution at 1 mg/mL) by rapid direct injection.</p>
<p style="text-indent:-2em;margin-left:4em;">Continuous IV infusion: Administer via an infusion pump.</p></div>
<div class="block adm drugH1Div" id="F233652"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">IV: For IV administration only; do not administer IM. Concentration of 1 mg/mL may be administered by rapid IV injection; may also be used for IV infusion in fluid-restricted patients.</p></div>
<div class="block uicn drugH1Div" id="F14473226"><span class="drugH1">Usual Infusion Concentrations: Neonatal</span>
<p style="text-indent:0em;display:inline">
<b>IV infusion:</b> 1 mg/mL</p></div>
<div class="block uicp drugH1Div" id="F14473225"><span class="drugH1">Usual Infusion Concentrations: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>IV infusion:</b> 0.1 mg/mL, 0.2 mg/mL, 1 mg/mL</p></div>
<div class="block sts drugH1Div" id="F233665"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store intact vials at 20°C to 25°C (68°F to 77°F). Vials reconstituted with bacteriostatic water for injection (BWFI) may be stored for 5 days under refrigeration or at room temperature. Vials reconstituted with other compatible diluents (including D5W, D5NS, LR, NS) should be stored under refrigeration and used within 24 hours. According to the 2020 to 2021 <i>ISMP Targeted Medication Safety Best Practices for Hospitals</i>, neuromuscular blockers should be segregated, sequestered, and differentiated from all other medication wherever they are stored.</p></div>
<div class="block usep drugH1Div" id="F53569434"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Adjunct to general anesthesia to facilitate endotracheal intubation and provide skeletal muscle relaxation during surgery or mechanical ventilation (FDA approved in ages &gt;7 weeks to 16 years and adults).</p></div>
<div class="block mst drugH1Div" id="F233715"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Vecuronium may be confused with valproate sodium, vancomycin</p>
<p style="text-indent:-2em;margin-left:4em;">Norcuron may be confused with Narcan</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Other safety concerns:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">According to the 2020 to 2021 ISMP targeted medication safety best practices for hospitals, neuromuscular blockers should be segregated, sequestered, and differentiated from all other medication wherever they are stored. This includes:</p>
<p style="text-indent:-2em;margin-left:6em;">Only storing in places within the hospital that they are routinely used.</p>
<p style="text-indent:-2em;margin-left:6em;">Placing in sealed boxes or in rapid-sequence intubation kits (preferred).</p>
<p style="text-indent:-2em;margin-left:6em;">Limiting availability in automated dispensing cabinets to perioperative, labor and delivery, critical care, and emergency departments only.</p>
<p style="text-indent:-2em;margin-left:6em;">Placing in separate lidded containers within the pharmacy refrigerator or other isolated pharmacy storage area.</p>
<p style="text-indent:-2em;margin-left:6em;">Affixing an auxiliary label to clearly communicate respiratory paralysis will occur and ventilation required on all storage bins and/or automated dispensing pockets/drawers (exception anesthesia-prepared syringes) stating one of the following:</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Warning: Causes Respiratory Arrest – Patient Must Be Ventilated.</b></p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Warning: Paralyzing Agent – Causes Respiratory Arrest.</b></p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Warning: Causes Respiratory Paralysis – Patient Must Be Ventilated.</b></p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13300211"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F233643"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Acetylcholinesterase Inhibitors: May diminish the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aminoglycosides: May enhance the therapeutic effect of Neuromuscular-Blocking Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bacitracin (Systemic): May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Botulinum Toxin-Containing Products: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Calcium Channel Blockers: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Capreomycin: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CarBAMazepine: May decrease the serum concentration of Vecuronium.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cardiac Glycosides: Neuromuscular-Blocking Agents may enhance the arrhythmogenic effect of Cardiac Glycosides. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clindamycin (Topical): May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Colistimethate: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. Management: If possible, avoid concomitant use of these products. Monitor for deeper, prolonged neuromuscular-blocking effects (respiratory paralysis) in patients receiving concomitant neuromuscular-blocking agents and colistimethate.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Corticosteroids (Systemic): Neuromuscular-Blocking Agents (Nondepolarizing) may enhance the adverse neuromuscular effect of Corticosteroids (Systemic). Increased muscle weakness, possibly progressing to polyneuropathies and myopathies, may occur.  Management: If concomitant therapy is required, use the lowest dose for the shortest duration to limit the risk of myopathy or neuropathy. Monitor for new onset or worsening muscle weakness, reduction or loss of deep tendon reflexes, and peripheral sensory decriments<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CycloSPORINE (Systemic): May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dantrolene: May enhance the neuromuscular-blocking effect of Vecuronium.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fosphenytoin-Phenytoin: May diminish the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing). Fosphenytoin-Phenytoin may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing). Fosphenytoin-Phenytoin may decrease the serum concentration of Neuromuscular-Blocking Agents (Nondepolarizing).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inhalational Anesthetics: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing). Management: When initiating a non-depolarizing neuromuscular blocking agent (NMBA) in a patient receiving an inhalational anesthetic, initial NMBA doses should be reduced 15% to 25% and doses of continuous infusions should be reduced 30% to 60%.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ketorolac (Nasal): May enhance the adverse/toxic effect of Neuromuscular-Blocking Agents (Nondepolarizing). Specifically, episodes of apnea have been reported in patients using this combination.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ketorolac (Systemic): May enhance the adverse/toxic effect of Neuromuscular-Blocking Agents (Nondepolarizing). Specifically, episodes of apnea have been reported in patients using this combination.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lincosamide Antibiotics: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lithium: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Local Anesthetics: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Loop Diuretics: May diminish the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. Loop Diuretics may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Magnesium Salts: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">MetroNIDAZOLE (Systemic): May enhance the neuromuscular-blocking effect of Vecuronium.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Minocycline (Systemic): May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ornidazole: May enhance the neuromuscular-blocking effect of Vecuronium.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pholcodine: May enhance the adverse/toxic effect of Neuromuscular-Blocking Agents. Specifically, anaphylaxis has been reported.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Piperacillin: May enhance the neuromuscular-blocking effect of Vecuronium.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polymyxin B: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. Management: If possible, avoid concomitant use of neuromuscular-blocking agents and polymyxin B. If concomitant use cannot be avoided, monitor for deeper, prolonged neuromuscular-blocking effects (eg, respiratory paralysis) in patients receiving this combination.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Procainamide: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QuiNIDine: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QuiNINE: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tetracyclines: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiazide and Thiazide-Like Diuretics: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trimebutine: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vancomycin: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F233658"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">The pharmacokinetics of vecuronium are altered during pregnancy. Use in cesarean section has been reported; umbilical venous concentrations were 11% of maternal values at delivery.</p></div>
<div class="block mopp drugH1Div" id="F53569433"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Assisted ventilation status, heart rate, blood pressure, muscle twitch response to peripheral nerve stimulation.</p></div>
<div class="block pha drugH1Div" id="F233638"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Blocks acetylcholine from binding to receptors on motor endplate inhibiting depolarization</p></div>
<div class="block phk drugH1Div" id="F233654"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action:</p>
<p style="text-indent:-2em;margin-left:4em;">Good intubation conditions: Within 2 to 3 minutes (Price 2012).</p>
<p style="text-indent:-2em;margin-left:4em;">Maximum neuromuscular blockade: Within 3 to 5 minutes.</p>
<p style="text-indent:-2em;margin-left:2em;">Duration: Under balanced anesthesia (time to recovery to 25% of control): 25 to 40 minutes; recovery 95% complete ~45 to 65 minutes after injection of intubating dose; hypothermia may prolong the duration of action.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: 0.3 to 0.4 L/kg.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 60% to 80%.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Active metabolite: 3-desacetyl vecuronium (<sup>1</sup>/<sub>2</sub> the activity of parent drug).</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life, elimination:</p>
<p style="text-indent:-2em;margin-left:4em;">Infants: 65 minutes.</p>
<p style="text-indent:-2em;margin-left:4em;">Children: 41 minutes.</p>
<p style="text-indent:-2em;margin-left:4em;">Healthy adult surgical patients and renal failure patients undergoing transplant surgery: 65 to 75 minutes; Late pregnancy: 35 to 40 minutes.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life, distribution: Adults: 4 minutes.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Primarily feces (35% to 50%); urine (15% to 50% as unchanged drug and metabolites) (Price 2012).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F233659"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Norcuron</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Bromuro de vecuronio pharmavial | Gobbicuronio | Rivecrum | Vecuronio northia</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Norcuron</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Norcuron | Vecure | Vecuronium sun</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Norcuron | Norq | Survec | Vencur</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Norcuron</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Norcuron</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Norcuron | Vecuron | Veronio</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Norcuron</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Norcuron</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Norcuron | Wei Da Song | Xian lin</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Bromuro de vecuronio | Nodescron | Norcuron | Vecuronio Bromuro</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Norcuron</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Norcuron | Vecuronium | Vecuronium bradex | Vecuronium Hikma</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Vecuron</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Norcuron</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Norcuron | Vecuronium inresa</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Norcuron</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Norcuron</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Norcuron</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Norcuron | Vecuronium sun</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Norcuron</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Norcuron</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Norcuron</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Norcuron</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Ecron | Norcuron</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Norcuron</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Norcuron</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Flexivec | Kabivec | Krovec | Naprovec | Neovec | Norcuron | Survec | Troyvec | Vecubro | Vecuron | Veronate | Vibro</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Norcuron</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Musculax | Muscurate | Muscurate maruishi</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Neovec | Norcuron | Samvec | Vecuron</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Norcuron | Vecaron | Vecaronin | Vecron | Vecuron | Vecuronium | Veroni</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Norcuron</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Norcuron</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Norcuron</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Norcuron</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Bromivec | Curlem | Doxcurom | Nodescron | Norcuron | Vecuronio | Zellax</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Norcuron</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Norcuron</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Norcuron | Vecuronium inresa | Vecuronium nordic prime</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Vecure | Vecuronium</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Vecaron | Vecubrom | Vecuronio Bromuro</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Norcuron | Noruvec</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Norcuron</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Norcuron | Vecuronium inresa</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Norcuron</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Norcuron</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Nodescron | Vecural</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Norcuron</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Norcuron</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Norcuron</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Norcuron</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Norcuron</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Norcuron | Vecuronium inresa</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Norcuron</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Norcuron</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Blok l | Norcuron | Vecron | Vecubloc</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Norcuron</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Norcuron</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Galaren | Vecural</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Norcuron | Prorelax | Vecuron | Vecuronio Bromuro</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Norcuron</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-11487763">
<a name="11487763"></a>Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vecuronium-pediatric-drug-information/abstract-text/11487763/pubmed" id="11487763" target="_blank">11487763</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ASHP.1">
<a name="ASHP.1"></a>American Society of Health-System Pharmacists (ASHP). Pediatric continuous infusion standards. Available at https://www.ashp.org/-/media/assets/pharmacy-practice/s4s/docs/Pediatric-Infusion-Standards.ashx. Updated January 2021. Accessed January 7, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11856794">
<a name="11856794"></a>Bernard SA, Gray TW, Buist MD, et al, “Treatment of Comatose Survivors of Out-of-Hospital Cardiac Arrest with Induced Hypothermia,” <i>N Engl J Med</i>, 2002, 346(8):557-63.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vecuronium-pediatric-drug-information/abstract-text/11856794/pubmed" id="11856794" target="_blank">11856794</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6810084">
<a name="6810084"></a>Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol—United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a>
<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vecuronium-pediatric-drug-information/abstract-text/6810084/pubmed" id="6810084" target="_blank">6810084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2827933">
<a name="2827933"></a>Costarino AT, Polin RA. Neuromuscular relaxants in the neonate. <i>Clin Perinatol</i>. 1987;14(4):965-989.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vecuronium-pediatric-drug-information/abstract-text/2827933/pubmed" id="2827933" target="_blank">2827933</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2574099">
<a name="2574099"></a>Darrah WC, Johnston JR, Mirakhur RK, “Vecuronium Infusions for Prolonged Muscle Relaxation in the Intensive Care Unit,” <i>Crit Care Med</i>, 1989, 17(12):1297-300.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vecuronium-pediatric-drug-information/abstract-text/2574099/pubmed" id="2574099" target="_blank">2574099</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Eichenwald.2017">
<a name="Eichenwald.2017"></a>Eichenwald EC, ed. <i>Cloherty and Stark's Manual of Neonatal Care</i>. 8th ed. Philadelphia, PA: Lippincott Williams &amp; Wilkins; 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2571460">
<a name="2571460"></a>Eldadah MK and Newth CJ, “Vecuronium by Continuous Infusion for Neuromuscular Blockade in Infants and Children,” <i>Crit Care Med</i>, 1989, 17(10):989-92.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vecuronium-pediatric-drug-information/abstract-text/2571460/pubmed" id="2571460" target="_blank">2571460</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14625670">
<a name="14625670"></a>Erstad BL, “Dosing of Medications in Morbidly Obese Patients in the Intensive Care Unit Setting,” <i>Intensive Care Med</i>, 2004, 30(1):18-32.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vecuronium-pediatric-drug-information/abstract-text/14625670/pubmed" id="14625670" target="_blank">14625670</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOO">
<a name="Expert.DOO"></a>Expert opinion. Senior Obesity Editorial Team: Jeffrey F. Barletta, PharmD, FCCM; Manjunath P. Pai, PharmD, FCP; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2858278">
<a name="2858278"></a>Fisher DM, Castagnoli K, Miller RD. Vecuronium kinetics and dynamics in anesthetized infants and children. <i>Clin Pharmacol Ther</i>. 1985;37(4):402-406.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vecuronium-pediatric-drug-information/abstract-text/2858278/pubmed" id="2858278" target="_blank">2858278</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1673644">
<a name="1673644"></a>Fitzpatrick KT, Black GW, Crean PM, Mirakhur RK. Continuous vecuronium infusion for prolonged muscle relaxation in children. <i>Can J Anaesth</i>. 1991;38(2):169-174.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vecuronium-pediatric-drug-information/abstract-text/1673644/pubmed" id="1673644" target="_blank">1673644</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23591211">
<a name="23591211"></a>Greenberg SB, Vender J. The use of neuromuscular blocking agents in the ICU: where are we now? <i>Crit Care Med</i>. 2013;41(5):1332-1344.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vecuronium-pediatric-drug-information/abstract-text/23591211/pubmed" id="23591211" target="_blank">23591211</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19029093">
<a name="19029093"></a>Han TH, Martyn JAJ. Onset and effectiveness of rocuronium for rapid onset of paralysis in patients with major burns: priming or large bolus. <i>Br J Anaesth</i>. 2009;102(1):55-60.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vecuronium-pediatric-drug-information/abstract-text/19029093/pubmed" id="19029093" target="_blank">19029093</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2571309">
<a name="2571309"></a>Harrison MJ, Gunn K. Weight determined dosage of vecuronium bromide. <i>Anaesthesia</i>. 1989;44(8):692. doi:10.1111/j.1365-2044.1989.tb13602.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vecuronium-pediatric-drug-information/abstract-text/2571309/pubmed" id="2571309" target="_blank">2571309</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2861836">
<a name="2861836"></a>Hunter JM, Parker CJR, Bess CF, et al, “The Use of Different Doses of Vecuronium in Patients With Liver Dysfunction,” <i>Br J Anaesth</i>, 1985, 57(8):758-64.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vecuronium-pediatric-drug-information/abstract-text/2861836/pubmed" id="2861836" target="_blank">2861836</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ISMP.2020">
<a name="ISMP.2020"></a>Institute for Safe Medication Practices (ISMP). 2020-2021 ISMP targeted medication safety best practices for hospitals. https://ismp.org/guidelines/best-practices-hospitals. Published February 21, 2020. Accessed August 4, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20176672">
<a name="20176672"></a>Kumar P, Denson SE, Mancuso TJ, et al, "Premedication for Nonemergency Endotracheal Intubation in the Neonate," <i>Pediatrics</i>, 2010, 125(3):608-15.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vecuronium-pediatric-drug-information/abstract-text/20176672/pubmed" id="20176672" target="_blank">20176672</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>"Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vecuronium-pediatric-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10446832">
<a name="10446832"></a>Martin LD, Bratton SL, O’Rourke PP. Clinical Uses and Controversies of Neuromuscular Blocking Agents in Infants and Children. <i>Crit Care Med.</i> 1999;27(7):1358-1368.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vecuronium-pediatric-drug-information/abstract-text/10446832/pubmed" id="10446832" target="_blank">10446832</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Miller.2010">
<a name="Miller.2010"></a>Miller RD. <i>Miller’s Anesthesia</i>, 7th ed. Philadelphia PA: Churchill Livingstone, 2010.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11902255">
<a name="11902255"></a>Murray MJ, Cowen J, DeBlock H, et al, “Clinical Practice Guidelines for Sustained Neuromuscular Blockade in the Adult Critically Ill Patient. Task Force of the American College of Critical Care Medicine (ACCM) of the Society of Critical Care Medicine (SCCM), American Society of Health-System Pharmacists, American College of Chest Physicians,” <i>Crit Care Med</i>, 2002, 30(1):142-56.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vecuronium-pediatric-drug-information/abstract-text/11902255/pubmed" id="11902255" target="_blank">11902255</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27755068">
<a name="27755068"></a>Murray MJ, DeBlock H, Erstad B, et al. Clinical practice guidelines for sustained neuromuscular blockade in the adult critically ill patient. <i>Crit Care Med</i>. 2016;44(11):2079-2103. doi: 10.1097/CCM.0000000000002027.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vecuronium-pediatric-drug-information/abstract-text/27755068/pubmed" id="27755068" target="_blank">27755068</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25147175">
<a name="25147175"></a>Murray KL, Wright D, Laxton B, Miller KM, Meyers J, Englebright J. Implementation of standardized pediatric i.v. medication concentrations.<i> Am J Health Syst Pharm</i>. 2014;71(17):1500-1508.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vecuronium-pediatric-drug-information/abstract-text/25147175/pubmed" id="25147175" target="_blank">25147175</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11753022">
<a name="11753022"></a>Naguib M, Flood P, McArdle JJ, Brenner HR. Advances in neurobiology of the neuromuscular junction. Implications for the anesthesiologist. <i>Anesthesiology</i>. 2002;96(1):202-31.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vecuronium-pediatric-drug-information/abstract-text/11753022/pubmed" id="11753022" target="_blank">11753022</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12847056">
<a name="12847056"></a>Nolan JP, Morley PT, Vanden Hoek TL, et al, “Therapeutic Hypothermia After Cardiac Arrest: An Advisory Statement by the Advanced Life Support Task Force of the International Liaison Committee on Resuscitation,” <i>Circulation</i>, 2003, 108(1):118-21.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vecuronium-pediatric-drug-information/abstract-text/12847056/pubmed" id="12847056" target="_blank">12847056</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22058104">
<a name="22058104"></a>Phillips MS, “Standardizing I.V. Infusion Concentrations: National Survey Results,” <i>Am J Health Syst Pharm</i>, 2011, 68(22):2176-82.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vecuronium-pediatric-drug-information/abstract-text/22058104/pubmed" id="22058104" target="_blank">22058104</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16390927">
<a name="16390927"></a>Phillips MS and Williams RL, “Improving the Safety of Neuromuscular Blocking Agents: A Statement from the USP Safe Medication Use Expert Committee,” <i>Am J Health Syst Pharm</i>, 2006, 63(2):139-42.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vecuronium-pediatric-drug-information/abstract-text/16390927/pubmed" id="16390927" target="_blank">16390927</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17683408">
<a name="17683408"></a>Playfor S, Jenkins I, Boyles C, et al. Consensus guidelines for sustained neuromuscular blockade in critically ill children. <i>Paediatr Anaesth</i>. 2007;17(9):881-887.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vecuronium-pediatric-drug-information/abstract-text/17683408/pubmed" id="17683408" target="_blank">17683408</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19237924">
<a name="19237924"></a>Polderman KH and Herold I, “Therapeutic Hypothermia and Controlled Normothermia in the Intensive Care Unit: Practical Considerations, Side Effects, and Cooling Methods,” <i>Crit Care Med</i>, 2009, 37(3):1101-20.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vecuronium-pediatric-drug-information/abstract-text/19237924/pubmed" id="19237924" target="_blank">19237924</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23062076">
<a name="23062076"></a>Price D, Kenyon NJ, Stollenwerk N. A fresh look at paralytics in the critically ill: real promise and real concern. <i>Ann Intensive Care</i>. 2012;2(1):43. doi:10.1186/2110-5820-2-43<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vecuronium-pediatric-drug-information/abstract-text/23062076/pubmed" id="23062076" target="_blank">23062076</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15505447">
<a name="15505447"></a>Reich DL, Hollinger I, Harrington DJ, Seiden HS, Chakravorti S, Cook DR. Comparison of cisatracurium and vecuronium by infusion in neonates and small infants after congenital heart surgery. <i>Anesthesiology</i>. 2004;101(5):1122-1127.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vecuronium-pediatric-drug-information/abstract-text/15505447/pubmed" id="15505447" target="_blank">15505447</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8835051">
<a name="8835051"></a>Rudis MI, Guslits BG, and Zarowitz BJ, “Technical and Interpretive Problems of Peripheral Nerve Stimulation in Monitoring Neuromuscular Blockade in the Intensive Care Unit,” <i>Ann Pharmacother</i>, 1996, 30(2):165-72.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vecuronium-pediatric-drug-information/abstract-text/8835051/pubmed" id="8835051" target="_blank">8835051</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9142020">
<a name="9142020"></a>Rudis MI, Sikora CA, Angus E, et al, “A Prospective, Randomized, Controlled Evaluation of Peripheral Nerve Stimulation Versus Standard Clinical Dosing of Neuromuscular Blocking Agents in Critically Ill Patients,” <i>Crit Care Med</i>, 1997, 25(4), 575-83.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vecuronium-pediatric-drug-information/abstract-text/9142020/pubmed" id="9142020" target="_blank">9142020</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1348166">
<a name="1348166"></a>Schwartz AE, Matteo RS, Ornstein E, Halevy JD, Diaz J. Pharmacokinetics and pharmacodynamics of vecuronium in the obese surgical patient. <i>Anesth</i>
<i>Analg</i>. 1992;74(4):515-518. doi:10.1213/00000539-199204000-00008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vecuronium-pediatric-drug-information/abstract-text/1348166/pubmed" id="1348166" target="_blank">1348166</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1353252">
<a name="1353252"></a>Segredo V, Caldwell JE, Matthay MA, et al, “Persistent Paralysis in Critically Ill Patients After Long-term Administration of Vecuronium,” <i>N Engl J Med</i>, 1992, 327(8):524-28.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vecuronium-pediatric-drug-information/abstract-text/1353252/pubmed" id="1353252" target="_blank">1353252</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Siegel.2018">
<a name="Siegel.2018"></a>Siegel MD. Acute respiratory distress syndrome: supportive care and oxygenation in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="https://www.uptodate.com" target="_blank">https://www.uptodate.com</a>. Accessed February 15, 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Sinclair.2007">
<a name="Sinclair.2007"></a>Sinclair-Pingel J, Grisso AG, Hargrove FR, Wright L. Implementation of standardized concentrations for continuous infusions using a computerized provider Order Entry System [published correction appears in <i>Hosp Pharm</i>. 2007; 42:84-85]. <i>Hosp Pharm</i>. 2006;41:1102- 106.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16782976">
<a name="16782976"></a>Suzuki T, Masaki G, Ogawa S. Neostigmine-induced reversal of vecuronium in normal weight, overweight and obese female patients. <i>Br J Anaesth</i>. 2006;97(2):160-163. doi:10.1093/bja/ael142<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vecuronium-pediatric-drug-information/abstract-text/16782976/pubmed" id="16782976" target="_blank">16782976</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AuroMedics.1">
<a name="AuroMedics.1"></a>Vecuronium [prescribing information]. E Windsor, NJ: AuroMedics Pharma LLC; October 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Mylan.1">
<a name="Mylan.1"></a>Vecuronium [prescribing information]. Rockford, IL: Mylan; July 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2904232">
<a name="2904232"></a>Weinstein JA, Matteo RS, Ornstein E, Schwartz AE, Goldstoff M, Thal G. Pharmacodynamics of vecuronium and atracurium in the obese surgical patient. <i>Anesth Analg</i>. 1988;67(12):1149-1153.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vecuronium-pediatric-drug-information/abstract-text/2904232/pubmed" id="2904232" target="_blank">2904232</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 12877 Version 293.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
